U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07197580) titled 'Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC' on Aug. 18.
Brief Summary: Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy aligned with Australian standard-of-care.
Study Start Date: Nov. 15
Study Type: INTERVENTIONAL
Condition:
ccRCC
Renal Cell Carcinoma (Kidney Cancer)
Renal Cell Carcinoma (RCC)
Renal Cell Cancer Metastatic
Renal Cell Cance...